Meditor Pharmaceuticals Ltd. – Product Pipeline Review – Q1 2011
Global Market Direct’s pharmaceuticals report, “Meditor Pharmaceuticals Ltd. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
- Meditor Pharmaceuticals Ltd. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Meditor Pharmaceuticals Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Meditor Pharmaceuticals Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Meditor Pharmaceuticals Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Meditor Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Meditor Pharmaceuticals Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Meditor Pharmaceuticals Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pi
Meditor Pharmaceuticals Ltd. – Product Pipeline Review – Q1 2011 Reference Code: GMDHC0284CDB Publication Date: MAR 2011 Meditor Pharmaceuticals Ltd. – Product Pipeline Review – Q1 2011 GMDHC0284CDB / Published MAR 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Meditor Pharmaceuticals Ltd. – Product Pipeline Review Ta b le o f Co n te n ts Table of Contents 2 List of Tables 3 List of Figures 3 Meditor Pharmaceuticals Ltd. Snapshot 4 Meditor Pharmaceuticals Ltd. Overview 4 Key Information 4 Key Facts 4 Meditor Pharmaceuticals Ltd. – Research and Development Overview 5 Key Therapeutic Areas 5 Meditor Pharmaceuticals Ltd. – Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products – Monotherapy 8 Meditor Pharmaceuticals Ltd. – Pipeline Products Glance 9 Meditor Pharmaceuticals Ltd. Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Meditor Pharmaceuticals Ltd. – Drug Profiles 10 MTR-106 10 Product Description 10 Mechanism of Action 10 R&D Progress 10 MTR105 11 Product Description 11 Mechanism of Action 11 R&D Progress 11 MTR107 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 Meditor Pharmaceuticals Ltd. – Pipeline Analysis 14 Meditor Pharmaceuticals Ltd. – Pipeline Products by Therapeutic Class 14 Meditor Pharmaceuticals Ltd. – Pipeline Products by Route of Administration 15 Meditor Pharmaceuticals Ltd. – Locations And Subsidiaries 16 Head Office 16 Other Locations & Subsidiaries 16 Recent Developments 17 Jun 12, 2008: Meditor Pharmaceuticals Ltd Reports Positive Results from Phase II Migraine Trial 17 Jun 11, 2008: MTR106 Tablets Were Found To Be Effective In Acute Migraine Attacks 17 Nov 06, 2007: A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets The Clinical Endpoints Of MTR106 Tablets During the Treatment Of Acute Migraine Attacks Without Aura In Females 18 Oct 04, 2006: Meditor Pharmaceuticals Provides Updates On Phase II Eastern European Clinical Study To Assess The Pharmacokinetics and Pharmacodynamics Of Orally Administered MTR106 18 Sep 27, 2006: Meditor Pharmaceuticals Provides Update on Phase II Trial Assessing the Pharmacokinetic and Pharmacodynamic Effects of Intravenously Administered MTR107 in ESRD Patients 18 Appendix 20 Methodology 20 Coverage 20 Secondary Research 20 Meditor Pharmaceuticals Ltd. – Product Pipeline Review – Q1 2011 GMDHC0284CDB / Published MAR 2011 ©Global Markets Direct.. This report is a licensed product and is not to be photocopied Page(2) Meditor Pharmaceuticals Ltd. – Product Pipeline Review Primary Research 20 Expert Panel Validation 21 Contact Us
Pages to are hidden for
"Meditor Pharmaceuticals Ltd. – Product Pipeline Review – Q1 2011"Please download to view full document